PDCD1 and neoplasm: Finally, in contrast to previous data suggesting that non-tumor-selective MEK inhibition in combination with anti-PD-1 treatment blocked T cell expansion and priming in vivo despite anti-tumor activity [94], Canon et al. found that AMG510 increased T cell priming, antigen recognition of tumor cells, and led to potential establishment of long-term tumor-specific T cell adaptive immune responses.